register

News & Trends - Pharmaceuticals

Vertex secures TGA approval for Cystic Fibrosis therapy

Health Industry Hub | March 26, 2021 |

Pharma News: Vertex Pharmaceuticals secured the Australian Therapeutic Goods Administration (TGA) approval of its Cystic Fibrosis drug.

TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), triple-combination drug, is indicated for people with Cystic Fibrosis (CF) ages 12 years and older who have at least one F508del mutation in the CF transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation worldwide. Up to 90% of people living with CF worldwide have at least one F508del mutation.

“We are delighted the TGA has approved TRIKAFTA for eligible people living with CF in Australia and will continue working with the Australian government to bring this important medicine to patients as quickly as possible,” said Reshma Kewalramani, M.D., Chief Executive Officer and President, Vertex. “It is our goal to develop and provide treatments for all people with CF around the world, and today is another significant milestone on that journey.”

CF affects approximately 3,500 people in Australia. It is caused by a defective and/or missing CFTR protein resulting from mutations in the CFTR gene.

Professor John Wilson AM, Head, Cystic Fibrosis Service, Alfred Health said “Cystic fibrosis is a complex, progressive, devastating disease that causes severe damage to the lungs, digestive system and other organs in the body. It is a condition that significantly affects not only the patient, but also those who care for them, with people living with cystic fibrosis spending multiple hours every day on treatment and requiring daily care from a family member or loved one.

“The approval of any new treatment option for people living with cystic fibrosis is always welcome news. This new treatment is for patients ages 12 years and older with at least one F508del mutation and means more patients can potentially benefit from a medicine that targets the underlying cause of the disease, for the first time.”

Lauren Carey, Country Manager Australia & New Zealand, Vertex Pharmaceuticals, said “We think the announcement will be well received by Australians living with cystic fibrosis. This approval by the TGA is the first important step in the process of seeking reimbursed access to TRIKAFTA.”

Trikafta’s first full year on the global market proved a huge success during which its $3.9 billion revenue globally increased Vertex’s total sales by 55% to $6.2 billion.

At this year’s J.P. Morgan healthcare conference, Vertex CEO Dr Reshma Kewalramani said the company was actively scouting for “tools and technology” to acquire, specifically mid- and late-stage assets to boost its pipeline beyond CF.


News & Trends - Pharmaceuticals

Clinicians unveil Novartis and BMS practice-changing trial results

Clinicians unveil Novartis and BMS practice-changing trial results

Health Industry Hub | June 24, 2024 |

Pharma News: Australia, known for its alarming melanoma rates, witnesses one person diagnosed with the disease every 30 minutes, and […]

More


News & Trends - Pharmaceuticals

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Health Industry Hub | June 24, 2024 |

Pharma News: Heart failure is a significant health concern in Australia, affecting approximately half a million people, with over 67,000 […]

More


News & Trends - MedTech & Diagnostics

Cardiologists mark Australian first with Boston Scientific's intracoronary imaging system

Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

Health Industry Hub | June 24, 2024 |

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices […]

More


Leadership & Management

AbbVie New Zealand welcomes new leadership amid global moves

AbbVie New Zealand welcomes new leadership amid global moves

Health Industry Hub | June 24, 2024 |

Leadership & Management: In line with its global talent development plan, AbbVie has announced a significant change in leadership for […]

More


This content is copyright protected. Please subscribe to gain access.